Varian Medical Systems led the robotic-assisted ultrasound device developer's series C round, which also included Johnson & Johnson Innovation - JJDC.

Existing backer Kakao Ventures reinvested in the AI-based drug discovery technology developer as part of an $11.5m round led by Mirae Asset Capital.

Intel Capital and Texas Medical Center Venture Fund were among the participants in an $11.9m round for patient monitoring system developer Medical Informatics.

Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer that was co-led by V-Bio Ventures and Advent France Biotechnology.

SMBC, Shinsei Bank, Mitsubishi UFJ and Kyoto Chuo Shinkin all backed cancer therapy developer Chordia Therapeutics’ latest round, which follows a Takeda-backed series A.

Oncology therapeutics developer Fusion Pharmaceticals closed a $105 round, featuring several corporate investors. The deal forms part of the growing broad oncology space, which has seen much attention from corporate venturers in recent years.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Global University Venturing Deal Net rounds up the week’s smaller deals and tracks the startups emerging from universities and raising funding.

TechNovum will run from June to October 2019, providing the UTS institute’s faculty with assistance in validating their biomedical propositions for the market.

The biopharmaceutical developer floated at the top of its range and will secure $65.9m from existing backer Merck & Co through a private placement.